NervGen Aligns with FDA on Phase 3 Tetraplegia Trial, Bolstering Neurorepair Pipeline

Event summary

  • NervGen Pharma and the FDA have reached agreement on the design of RESTORE, a Phase 3 registrational study for NVG-291 in chronic tetraplegia.
  • The primary endpoint for RESTORE will be change from baseline in GRASSP Quantitative Prehension at Week 12, a functional measure of hand use.
  • Enrollment in the Phase 1b/2a CONNECT SCI study for subacute tetraplegia is concluding, with data to be unblinded.
  • The RESTORE trial is slated to begin in mid-2026, with study initiation activities already underway.
  • CONNECT SCI data showed a +3.7 point improvement in GRASSP QtP for NVG-291 versus +0.4 for placebo, exceeding the minimally important difference of 2.0 points.

The big picture

NervGen's progress represents a significant, albeit early, step toward a pharmacologic treatment for chronic tetraplegia, a condition affecting an estimated 12,000 people annually in the US alone. The FDA’s alignment on RESTORE’s design validates the CONNECT SCI data and provides a clearer path to potential approval, but the Phase 3 trial will be a critical test of NVG-291’s efficacy and safety. The broader neurorepair market is attracting increasing investment, but remains largely preclinical, making NervGen a potential early mover.

What we're watching

Clinical Execution
The success of RESTORE hinges on patient recruitment and retention across up to 60 sites, and the ability to demonstrate statistically significant and clinically meaningful improvements in GRASSP Quantitative Prehension.
Regulatory Pathway
The FDA’s alignment on endpoints could set a precedent for future SCI therapeutic approvals, but any deviations from the agreed-upon protocol could trigger further scrutiny and delay.
Commercialization
Given the limited treatment options and high unmet need for chronic tetraplegia, the commercial viability of NVG-291 will depend on demonstrating a compelling value proposition and navigating potential reimbursement challenges.

Related topics

Regulatory Approval Clinical Trial Regenerative Medicine